Chardan Capital analyst Daniil Gataulin maintained a Hold rating on Outlook Therapeutics (OTLK – Research Report) today and set a price target ...

Outlook Therapeutics Inc (OTLK) stock saw a decline, ending the day at $2.19 which represents a decrease of $-0.11 or -4.78% from the prior close of $2.3. The stock opened at $2.13 and touched a low ...

Outlook Therapeutics Inc (OTLK) stock saw a modest uptick, ending the day at $2.23 which represents a slight increase of $0.04 or 1.83% from the prior close of $2.19. The stock opened at $2.19 and ...

Outlook Therapeutics (OTLK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Douglas ...

Outlook Therapeutics, Inc. (NASDAQ:OTLK) completed the analysis of the complete 12-week safety and efficacy results for NORSE ...

Outlook Therapeutics (NASDAQ:OTLK) shares were down 10% Thursday morning after the company said it had completed an analysis ...

Outlook Therapeutics, Inc. (NASDAQ:OTLK – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the seven analysts that are currently covering the company, Marketbeat reports ...

OTLK has been the topic of a number of other research reports. BTIG Research lowered their price target on Outlook Therapeutics from $50.00 to $9.00 and set a “buy” rating on the stock in a ...

OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earli ...

Short interest in Outlook Therapeutics Inc (NASDAQ:OTLK) decreased during the last reporting period, falling from 4.13M to 3.51M. This put 21.82% of the company's publicly available shares short.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...